FISCAL DETERMINANTS OF GOVERNMENT BORROWING COSTS: DO WE HAVE ONLY OURSELVES TO BLAME?




Cost-effectiveness analysis of treatment timing considering the future entry of lower-cost generics for hepatitis C

Katherine Heath1,2 1Mathematical Ecology Research Group, Department of Zoology, University of Oxford, Oxford OX1 3PS, UK; 2New College, Oxford OX1 3BN, UK Background: Cost-benefit analyses are crucial to inform treatment policies, particularly when the cost of patented drugs is very high.The cost of patented drugs is the limiting factor in hepatiti

read more